| Molecule Name |
DB00888
|
| DrugBank Groups |
Approved
|
| Cluster No |
533
|
| Smiles |
ClCCN(CCCl)C
|
| Download |
mol2, pdbqt
|
| TPSA |
3,24
|
| Non-H Atoms |
8
|
| Non-C/H Atoms |
3
|
| Metal-Atoms |
0
|
| Electronegative Atoms |
3
|
| Stereo Centers |
0
|
| Rotatable Bonds |
4
|
| Rings Closures |
0
|
| Small Rings |
0
|
| Aromatic Rings |
0
|
| Aromatic Atoms |
0
|
| sp3-Atoms |
6
|
| Symmetric atoms |
3
|
| cLogS |
-1,209
|
| MW |
156,055
|
| cLogP |
1,1356
|
| HBA |
1
|
| HBD |
0
|
| Ro5 violations |
0
|
| Druglikeness |
4,5307
|
| DrugScore |
0,125175743086327
|
| Mutagenic |
high
|
| Tumorigenic |
high
|
| Reproductive Effective |
high
|
| Irritant |
high
|
| Blood-Brain Barrier |
BBB+
|
| Human Intestinal Absorption |
HIA+
|
| Caco-2 Permeability |
Caco2+
|
| P-glycoprotein Substrate |
Non-substrate
|
| P-glycoprotein Inhibitor |
Non-inhibitor
|
| P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
| Renal Organic Cation Transporter |
Inhibitor
|
| Aqueous solubility |
-1,944
|
| Caco-2 Permeability 2 |
1,2773
|
| Subcellular localization |
Lysosome
|
| CYP450 2C9 Substrate |
Non-substrate
|
| CYP450 2D6 Substrate |
Non-substrate
|
| CYP450 3A4 Substrate |
Non-substrate
|
| CYP450 1A2 Inhibitor |
Non-inhibitor
|
| CYP450 2C9 Inhibitor |
Non-inhibitor
|
| CYP450 2D6 Inhibitor |
Non-inhibitor
|
| CYP450 2C19 Inhibitor |
Non-inhibitor
|
| CYP450 3A4 Inhibitor |
Non-inhibitor
|
| CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
| Human Ether-a-go-go-Related Gene Inhibition |
Strong inhibitor
|
| Human Ether-a-go-go-Related Gene Inhibition 2 |
Non-inhibitor
|
| AMES Toxicity |
AMES toxic
|
| Carcinogens |
Carcinogens
|
| Fish Toxicity |
High FHMT
|
| Fish Toxicity (pLC50, mg/L) |
2,0102
|
| Tetrahymena Pyriformis Toxicity |
High TPT
|
| Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
-0,1701
|
| Honey Bee Toxicity |
Low HBT
|
| Biodegradation |
Not ready biodegradable
|
| Acute Oral Toxicity |
I
|
| Rat Acute Toxicity (LD50, mol/kg) |
4,1619
|
| Carcinogenicity (Three-class) |
Danger
|
